Myelin News and Research

RSS

Myelin is the fatty substance that covers and protects nerves.

Study confirms link between smoking and reduced risk of acoustic neuroma

New research confirms an association between smoking and a reduced risk for a rare benign tumor near the brain, but the addition of smokeless tobacco to the analysis suggests nicotine is not the protective substance.

24 Apr 2012

Nano-devices cross blood-brain barrier to deliver drug to treat cerebral palsy

A team of scientists from Johns Hopkins and elsewhere have developed nano-devices that successfully cross the brain-blood barrier and deliver a drug that tames brain-damaging inflammation in rabbits with cerebral palsy.

23 Apr 2012

Breakdown of white-matter pathways affects decision-making as we age

If you are an aging baby boomer and you've noticed it's a bit harder to drive to unfamiliar locations or to pick a new brand of olive oil at the supermarket, you can blame it on the white matter in your brain.

20 Apr 2012

Biogen Idec launches FAMPYRA in Canada

Today, Biogen Idec Canada announces that FAMPYRA (fampridine sustained release tablets or fampridine SR) is now available for prescription for patients living with multiple sclerosis (MS) in Canada.

12 Apr 2012

ACMG Foundation, Genzyme announce recipients of Medical Genetics Training Award

Carlos E. Prada, MD of Cincinnati Children's Hospital and James D. Weisfeld-Adams, MD of Mount Sinai School of Medicine, NY were honored as the 2012-2013 recipients of the Genzyme/ACMG Foundation Medical Genetics Training Award in Clinical Biochemical Genetics at the ACMG 2012 Annual Clinical Genetics Meeting in Charlotte, NC.

6 Apr 2012

JAK-STAT inhibitors reverse MS-like disease in mice

A new class of drugs completing clinical trials soon for rheumatoid arthritis should be examined as a treatment for multiple sclerosis, according to the authors of a University of Alabama at Birmingham study published today in the Proceedings of the National Academy of Sciences.

13 Mar 2012

MRF clinical trial to examine antigen-specific MS therapy

The Myelin Repair Foundation (MRF) announced today that its research might soon lead into a clinical proof-of-concept trial at the Department of Neuroimmunology and Multiple Sclerosis Research (nims), University Hospital Zürich, Switzerland, and the Institute for Neuroimmunology and Clinical Multiple Sclerosis Research (inims) in Hamburg, Germany.

8 Mar 2012

Opexa 2011 net loss increases to $5,968,448

Opexa Therapeutics, Inc., a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the year ended December 31, 2011 and provided an overview of corporate developments during the last year.

27 Feb 2012

Death of myelin sheath producing cells does not trigger MS

Millions of adults suffer from the incurable disease multiple sclerosis (MS). It is relatively certain that MS is an autoimmune disease in which the body's own defense cells attack the myelin in the brain and spinal cord.

27 Feb 2012

Computer-assisted cognitive rehabilitation benefits patients with relapsing-remitting MS

In a new study published in the March issue of Radiology, functional magnetic resonance imaging (fMRI) shows that cognitive rehabilitation changes brain function and improves cognitive performance in patients with relapsing-remitting multiple sclerosis (MS).

23 Feb 2012

Acorda's fourth quarter GAAP net income increases to $12.7 million

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2011.

16 Feb 2012

New WSU model system focuses on causes of everyday MS symptoms

Annoying, frustrating symptoms like difficulty hearing or remembering things can complicate everyday living for multiple sclerosis (MS) patients, but most research to date has focused on the disease's less frequent but more debilitating consequences.

15 Feb 2012

Cancer drug bexarotene effective in mouse model of Alzheimer’s

Case Western Reserve University School of Medicine neuroscientist Gary Landreth and colleagues reported Thursday that the drug - bexarotene quickly cleared away beta-amyloid plaque, believed to cause the cognitive deficits of Alzheimer's disease, from the brains of genetically engineered mice.

12 Feb 2012

Gene therapy to promote remyelination in mouse model of MS

Our bodies are full of tiny superheroes-antibodies that fight foreign invaders, cells that regenerate, and structures that ensure our systems run smoothly. One such structure is myelin-a material that forms a protective, insulating cape around the axons of our nerve cells so that they can send signals quickly and efficiently. But myelin, and the specialized cells called oligodendrocytes that make it, become damaged in demyelinating diseases like multiple sclerosis (MS), leaving neurons without their myelin sheaths.

10 Feb 2012

Converted umbilical cord stem cells hold hope for spinal cord injuries, multiple sclerosis

For the first time ever, stem cells from umbilical cords have been converted into other types of cells, which may eventually lead to new treatment options for spinal cord injuries and multiple sclerosis, among other nervous system diseases.

18 Jan 2012

Lack of iron early in life can affect brain's physical structure

Iron is a popular topic in health news. Doctors prescribe it for medical reasons, and it's available over the counter as a dietary supplement. And while it's known that too little iron can result in cognitive problems, it's also known that too much promotes neurodegenerative diseases. Now, researchers at UCLA have found that in addition to causing cognitive problems, a lack of iron early in life can affect the brain's physical structure as well.

12 Jan 2012

Study provides hope for stimulating remyelination in MS patients

Scientists at Joslin Diabetes Center, Harvard University, and the University of Cambridge have found that the age-related impairment of the body's ability to replace protective myelin sheaths, which normally surround nerve fibers and allow them to send signals properly, may be reversible, offering new hope that therapeutic strategies aimed at restoring efficient regeneration can be effective in the central nervous system throughout life.

7 Jan 2012

Age-associated decline of remyelination process may be reversible

New research highlights the possibility of reversing ageing in the central nervous system for multiple sclerosis (MS) patients. The study is published today, 06 January, in the journal Cell Stem Cell.

7 Jan 2012

New laboratory approach could aid brain recovery

In humans, active periods of the debilitating disease Multiple Sclerosis (MS) can last for mere minutes or extend to weeks at a time. They're caused by lesions in the brain that develop, partly heal, and then recur. Research into a cure has been difficult, because to date scientists have not been able to replicate these brain recurring symptoms in laboratory mice. That's frustrating because these lab animals, known as animal "models," are the primary tool for research into the mechanisms and potential treatments for MS.

6 Jan 2012

Faulty lipid metabolism may cause MS, says forensic anthropologist

An article to be published in the December 2011 issue of The Quarterly Review of Biology argues that multiple sclerosis, long viewed as primarily an autoimmune disease, is not actually a disease of the immune system.

23 Dec 2011